Drug Trial Radar · NCT07449936
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Feb 16, 2026
Primary completion
Oct 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
- Diabetic Macular Edema
- DME
- Diabetic Macular Edema (DME)
Interventions
EYP-1901Drug
Intravitreal Injection
Aflibercept (2.0 mg)Drug
Intravitreal Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average change in best corrected visual acuity (BCVA)Time frame: Weeks 52 and 56
Locations
73 sites in 5 countries. Site status is shown where the registry gives one.
California Retina Consultants
Bakersfield, California
The Retina Partners
Encino, California
Global Research Management, Inc.
Glendale, California
Northern California Retina Vitreous Associates Medical Group INC.
Mountain View, California
Retina Consultants of San Diego
Poway, California
California Eye Specialists Medical Group, Inc.
Redlands, California
Retinal Consultants Medical Group - Parkcenter Drive
Sacramento, California
Retinal Consultants Medical Group
Sacramento, California
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
Colorado Retina Associates
Lakewood, Colorado
Advanced Research LLC Sibia Eye Institute
Boynton Beach, Florida
Advance Medical Research Group, Inc
Deerfield Beach, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
Retina Vitreous Associates of Florida - Saint Petersburg
St. Petersburg, Florida
Southern Vitreoretinal Associates
Tallahassee, Florida
Retina Specialists of Tampa
Wesley Chapel, Florida
Georgia Retina
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Red River Research Partners
Plainfield, Illinois
Midwest Eye Institute - Carmel
Carmel, Indiana
Haik Humble Eye Center
West Monroe, Louisiana
Johns Hopkins Medicine - The Johns Hopkins Hospital Campus - Wilmer Eye Institute
Baltimore, Maryland
Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Retina Specialists - Towson
Towson, Maryland
New England Retina Consultants
Springfield, Massachusetts
Retina Associates of Michigan
Grand Blanc, Michigan
Foundation for Vision Research
Grand Rapids, Michigan
Sierra Eye Associates
Reno, Nevada
NJRetina Care Center - Teaneck
Teaneck, New Jersey
NJ Retina - Toms River
Toms River, New Jersey
Retina Associates of Western New York
Rochester, New York
VRCNY/Long Island Vitreoretinal Consultants
Westbury, New York
Asheville Eye Associates - Regional Medical Park
Asheville, North Carolina
Cape Fear Retinal Associates, PC
Wilmington, North Carolina
Piedmont Retina Specialists, P.A. - Winston-Salem Office
Winston-Salem, North Carolina
Tulsa Retina Consultant
Tulsa, Oklahoma
Erie Retina Research
Erie, Pennsylvania
Charleston Neuroscience Institute - Beaufort
Beaufort, South Carolina
Retina Consultants of Carolina P.A
Greenville, South Carolina
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.